JorgeBenitez
@benitezja.bsky.social
Passionate about #Science #Oncology #DrugDiscovery #protacs #ProteinDregradation #Neuroscience #cancer #organoids #pdx #epigenetics #omics
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer www.cell.com/cancer-cell/...
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer
Microsatellite stable BRAFV600E CRC is characterized by higher immune activation and
clinically poor prognosis. Morris et al. demonstrate durable clinical benefit to encorafenib,
cetuximab, and nivolu...
www.cell.com
November 11, 2025 at 2:37 PM
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer www.cell.com/cancer-cell/...
Long-range cholinergic input promotes glioblastoma progression www.cell.com/cancer-cell/...
Long-range cholinergic input promotes glioblastoma progression
Glioblastoma is shaped by neural integration. Using brain-wide input mapping, Yang
et al. reveal complex neuron-glioma connectivity and show that long-range cholinergic
input promotes tumor growth via...
www.cell.com
November 11, 2025 at 2:24 PM
Long-range cholinergic input promotes glioblastoma progression www.cell.com/cancer-cell/...
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. ascopubs.org/doi/10.1200/...
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAF<sup>V600E</sup>-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study.
8574Background: Patients (pts) with BRAFV600E mutated non-small cell lung cancer (NSCLC) can be effectively treated with BRAF and
MEK inhibitors (BRAFi+MEKi) or with immune checkpoint inhibitors ± che...
ascopubs.org
October 25, 2025 at 4:22 AM
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. ascopubs.org/doi/10.1200/...
Past, present and future of drug conjugates for cancer therapy www.nature.com/articles/s43...
Past, present and future of drug conjugates for cancer therapy - Nature Cancer
Neri and colleagues discuss the development of drug conjugates for cancer therapy, focusing on current and future opportunities to improve tumor-targeting efficacy with small molecule–drug conjugates ...
www.nature.com
October 25, 2025 at 4:20 AM
Past, present and future of drug conjugates for cancer therapy www.nature.com/articles/s43...
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment www.nature.com/articles/s41...
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment - Nature Reviews Cancer
Antibody–drug conjugates are rapidly expanding both in the clinical treatment of cancer and in preclinical development. In this Review, Zippelius et al. highlight the molecular interactions and immune...
www.nature.com
October 25, 2025 at 4:19 AM
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment www.nature.com/articles/s41...
Leveraging WNT Hyperactivation to Kill Colorectal Cancer While Rejuvenating Healthy Intestine www.biorxiv.org/content/10.1...
Leveraging WNT Hyperactivation to Kill Colorectal Cancer While Rejuvenating Healthy Intestine
WNT signaling maintains intestinal homeostasis yet drives colorectal cancer (CRC) when constitutively activated by APC mutations. We overturn the fundamental assumption that APC-mutant tumors exist at...
www.biorxiv.org
October 18, 2025 at 2:54 PM
Leveraging WNT Hyperactivation to Kill Colorectal Cancer While Rejuvenating Healthy Intestine www.biorxiv.org/content/10.1...
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. ascopubs.org/doi/10.1200/...
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAF<sup>V600E</sup>-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study.
8574Background: Patients (pts) with BRAFV600E mutated non-small cell lung cancer (NSCLC) can be effectively treated with BRAF and
MEK inhibitors (BRAFi+MEKi) or with immune checkpoint inhibitors ± che...
ascopubs.org
October 18, 2025 at 2:54 PM
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. ascopubs.org/doi/10.1200/...
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers www.cell.com/cancer-cell/...
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers
Feng et al. demonstrate the potent antitumor efficacy of MCB-294, a pan-KRAS inhibitor,
and MCB-36, a derivative proteolysis-targeting chimera (PROTAC) degrader. MCB-294
engages both active and inacti...
www.cell.com
October 18, 2025 at 2:53 PM
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers www.cell.com/cancer-cell/...
A chemical epigenetic tool to probe site-specific DNA-binding protein complexes www.pnas.org/doi/10.1073/...
PNAS
Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...
www.pnas.org
October 8, 2025 at 9:08 PM
A chemical epigenetic tool to probe site-specific DNA-binding protein complexes www.pnas.org/doi/10.1073/...
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer www.science.org/doi/10.1126/...
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer
Gene expression programs directed by MYC mediate oncogenic KRAS signaling in pancreatic cancer.
www.science.org
October 3, 2025 at 11:44 PM
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer www.science.org/doi/10.1126/...
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study www.thelancet.com/journals/lan...
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
First-line ICIs with or without chemotherapy were associated with improved overall
survival compared with BRAF and MEK inhibitors in participants with metastatic BRAFV600E-mutated
NSCLC, particularly ...
www.thelancet.com
September 30, 2025 at 11:29 PM
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study www.thelancet.com/journals/lan...
Reposted by JorgeBenitez
De novo design of phospho-tyrosine peptide binders [new]
Designs binders for phosphorylated tyrosine sites on clinically relevant targets using a deep generative framework, enabling modulation of signaling pathways.
Designs binders for phosphorylated tyrosine sites on clinically relevant targets using a deep generative framework, enabling modulation of signaling pathways.
September 30, 2025 at 9:12 PM
De novo design of phospho-tyrosine peptide binders [new]
Designs binders for phosphorylated tyrosine sites on clinically relevant targets using a deep generative framework, enabling modulation of signaling pathways.
Designs binders for phosphorylated tyrosine sites on clinically relevant targets using a deep generative framework, enabling modulation of signaling pathways.
Reposted by JorgeBenitez
The top-ranked country this year, as it was last year, is tiny Switzerland. Sweden comes second and America third econ.st/46EuZKN
September 30, 2025 at 11:00 PM
The top-ranked country this year, as it was last year, is tiny Switzerland. Sweden comes second and America third econ.st/46EuZKN
How Much Water and Energy do Data Centers Consume? A New Jersey Bill Demands Answers. insideclimatenews.org/news/2409202...
How Much Water and Energy do Data Centers Consume? A New Jersey Bill Demands Answers. - Inside Climate News
If signed, the bill would make data centers release quarterly reports on water and electricity use.
insideclimatenews.org
September 28, 2025 at 4:22 PM
How Much Water and Energy do Data Centers Consume? A New Jersey Bill Demands Answers. insideclimatenews.org/news/2409202...
Combinatorial prediction of therapeutic perturbations using causally inspired neural networks www.nature.com/articles/s41...
Combinatorial prediction of therapeutic perturbations using causally inspired neural networks - Nature Biomedical Engineering
PDGrapher uses large datasets of genetic and chemical interventions to find genetic targets that shift a gene expression phenotype from a diseased to a normal state.
www.nature.com
September 25, 2025 at 1:22 AM
Combinatorial prediction of therapeutic perturbations using causally inspired neural networks www.nature.com/articles/s41...
Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability jamanetwork.com/journals/jam...
Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability
This nationwide cohort study with sibling control analysis examines the association of acetaminophen use during pregnancy with children’s risk of autism, ADHD, and intellectual disability.
jamanetwork.com
September 23, 2025 at 2:40 AM
Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability jamanetwork.com/journals/jam...
The immune microenvironment of colorectal cancer www.nature.com/articles/s41...
The immune microenvironment of colorectal cancer - Nature Reviews Cancer
In this Review, Kennel and Greten highlight the role of immune cells in colorectal cancer (CRC) development, progression and metastasis as well as the impact of therapies on the immune microenvironmen...
www.nature.com
September 22, 2025 at 3:22 PM
The immune microenvironment of colorectal cancer www.nature.com/articles/s41...
Aspirin led to a significantly lower incidence of colorectal cancer recurrence than placebo among patients with PIK3CA hotspot mutations www.nejm.org/doi/full/10....
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer | NEJM
Aspirin reduces the incidence of colorectal adenoma and colorectal cancer among high-risk persons. Observational studies suggest that aspirin may also improve disease-free survival after diagnosis,...
www.nejm.org
September 18, 2025 at 1:12 AM
Aspirin led to a significantly lower incidence of colorectal cancer recurrence than placebo among patients with PIK3CA hotspot mutations www.nejm.org/doi/full/10....
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer www.sciencedirect.com/science/arti...
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer
The BRAF inhibitor encorafenib and anti-epidermal growth factor receptor (EGFR) antibody cetuximab modestly improve survival for patients with microsa…
www.sciencedirect.com
September 3, 2025 at 12:56 PM
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer www.sciencedirect.com/science/arti...
Load and lock: An emerging class of therapeutics that influence macromolecular dissociation www.science.org/doi/10.1126/...
Load and lock: An emerging class of therapeutics that influence macromolecular dissociation
Biology is governed by macromolecular interactions, perturbation of which often lies at the heart of disease. Most therapeutic drugs, whether they are small molecules or biologics, exert their effects...
www.science.org
August 27, 2025 at 1:11 AM
Load and lock: An emerging class of therapeutics that influence macromolecular dissociation www.science.org/doi/10.1126/...
Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation www.sciencedirect.com/science/arti...
Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation
Glutarimide analogs, such as thalidomide, redirect the E3 ubiquitin ligase CRL4CRBN to induce degradation of certain zinc finger (ZF) proteins. Althou…
www.sciencedirect.com
August 26, 2025 at 5:20 AM
Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation www.sciencedirect.com/science/arti...
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer #proteindegradation #protacs aacrjournals.org/clincancerre...
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer
Abstract. Purpose: BMS-986365, a heterobifunctional AR LDD, was designed as a potent cereblon-dependent degrader and competitive antagonist of AR to overcome resistance to ARPIs in metastatic prostate...
aacrjournals.org
August 12, 2025 at 4:25 AM
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer #proteindegradation #protacs aacrjournals.org/clincancerre...
Arvinas rules out a solo vepdegestrant launch www.oncologypipeline.com/apexonco/arv...
Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
www.oncologypipeline.com
August 7, 2025 at 5:22 PM
Arvinas rules out a solo vepdegestrant launch www.oncologypipeline.com/apexonco/arv...
T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma
Broad-spectrum RAS inhibition acts in concert with the immune system to achieve deep antitumor responses.
aacrjournals.org
August 5, 2025 at 2:20 AM
T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
Why Your Name Matters www.newyorker.com/tech/annals-...
Why Your Name Matters
www.newyorker.com
August 1, 2025 at 2:58 PM
Why Your Name Matters www.newyorker.com/tech/annals-...